Charlotte Adams

Ms. Charlotte Adams

University of Antwerp, Antwerp, Flanders, Belgium
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Mass Spectrometry Reviews
Verified
Journal Article
Open access
DFDaniel Flender
Daniel Flender
FVFrédérique Vilenne
Frédérique Vilenne
CACharlotte Adams
Charlotte Adams
KBKurt Boonen
Kurt Boonen
Dirk ValkenborgDirk Valkenborg
Dirk Valkenborg
GBGeert Baggerman
Geert Baggerman
Immunopeptidomics is becoming an increasingly important field of study. The capability to identify immunopeptides with pivotal roles in the human immune system is essential to shift the current curative medicine towards personalized medicine. Throughout the years, the field has matured, giving insight into the current pitfalls. Nowadays, it is commonly accepted that generalizing shotgun proteomics workflows is malpractice because immunopeptidomics faces numerous challenges. While many of these difficulties have been addressed, the road towards the ideal workflow remains complicated. Although the presence of Posttranslational modifications (PTMs) in the immunopeptidome has been demonstrated, their identification remains highly challenging despite their significance for immunotherapies. The large number of unpredictable modifications in the immunopeptidome plays a pivotal role in the functionality and these challenges. This review provides a comprehensive overview of the current advancements in immunopeptidomics. We delve into the challenges associated with identifying PTMs within the immunopeptidome, aiming to address the current state of the field.

10 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CACharlotte Adams
Charlotte Adams
WGWassim Gabriel
Wassim Gabriel
KLKris Laukens
Kris Laukens
MPMario Picciani
Mario Picciani
MWMathias Wilhelm
Mathias Wilhelm
KBKurt Boonen
Kurt Boonen
Immunopeptidomics is crucial for immunotherapy and vaccine development. Because the generation of immunopeptides from their parent proteins does not adhere to clear-cut rules, rather than being able to use known digestion patterns, every possible protein subsequence within human leukocyte antigen (HLA) class-specific length restrictions needs to be considered during sequence database searching. This leads to an inflation of the search space and results in lower spectrum annotation rates. Peptide-spectrum match (PSM) rescoring is a powerful enhancement of standard searching that boosts the spectrum annotation performance. We analyze 302,105 unique synthesized non-tryptic peptides from the ProteomeTools project on a timsTOF-Pro to generate a ground-truth dataset containing 93,227 MS/MS spectra of 74,847 unique peptides, that is used to fine-tune the deep learning-based fragment ion intensity prediction model Prosit. We demonstrate up to 3-fold improvement in the identification of immunopeptides, as well as increased detection of immunopeptides from low input samples.

27 November 2023 in Proteomics
Verified
Journal Article
Open access
CACharlotte Adams
Charlotte Adams
KLKris Laukens
Kris Laukens
WBWout Bittremieux
Wout Bittremieux
KBKurt Boonen
Kurt Boonen
Immunopeptidomics is a key technology in the discovery of targets for immunotherapy and vaccine development. However, identifying immunopeptides remains challenging due to their non‐tryptic nature, which results in distinct spectral characteristics. Moreover, the absence of strict digestion rules leads to extensive search spaces, further amplified by the incorporation of somatic mutations, pathogen genomes, unannotated open reading frames, and post‐translational modifications. This inflation in search space leads to an increase in random high‐scoring matches, resulting in fewer identifications at a given false discovery rate. Peptide‐spectrum match rescoring has emerged as a machine learning‐based solution to address challenges in mass spectrometry‐based immunopeptidomics data analysis. It involves post‐processing unfiltered spectrum annotations to better distinguish between correct and incorrect peptide‐spectrum matches. Recently, features based on predicted peptidoform properties, including fragment ion intensities, retention time, and collisional cross section, have been used to improve the accuracy and sensitivity of immunopeptide identification. In this review, we describe the diverse bioinformatics pipelines that are currently available for peptide‐spectrum match rescoring and discuss how they can be used for the analysis of immunopeptidomics data. Finally, we provide insights into current and future machine learning solutions to boost immunopeptide identification.

29 July 2024 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
CDCeder Dens
Ceder Dens
CACharlotte Adams
Charlotte Adams
KLKris Laukens
Kris Laukens
WBWout Bittremieux
Wout Bittremieux

19 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CACharlotte Adams
Charlotte Adams
WGWassim Gabriel
Wassim Gabriel
KLKris Laukens
Kris Laukens
MPMario Picciani
Mario Picciani
MWMathias Wilhelm
Mathias Wilhelm
KBKurt Boonen
Kurt Boonen
Immunopeptidomics plays a crucial role in identifying targets for immunotherapy and vaccine development. Because the generation of immunopeptides from their parent proteins does not adhere to clear-cut rules, rather than being able to use known digestion patterns, every possible protein subsequence within human leukocyte antigen (HLA) class-specific length restrictions needs to be considered during sequence database searching. This leads to an inflation of the search space and results in lower spectrum annotation rates. Peptide-spectrum match (PSM) rescoring is a powerful enhancement of standard searching that boosts the spectrum annotation performance. Low abundant peptides often occur in the field of immunopeptidomics, which is why the highly sensitive timsTOF instruments are increasingly gaining popularity. To improve PSM rescoring for immunopeptides measured using timsTOF instruments, we trained a deep learning-based fragment ion intensity prediction model. 302,105 unique synthesized non-tryptic peptides from the ProteomeTools project were analyzed on a timsTOF-Pro to generate a ground-truth dataset, containing 93,227 MS/MS spectra of 74,847 unique peptides, that was used to fine-tune an existing Prosit model. By applying our fragment ion intensity prediction model, we demonstrate up to 3-fold improvement in the identification of immunopeptides. Furthermore, our approach increased detection of immunopeptides even from low input samples.

22 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
JHJhana O. Hendrickx
Jhana O. Hendrickx
CACharlotte Adams
Charlotte Adams
ASAnne Sieben
Anne Sieben
KLKris Laukens
Kris Laukens
DDDebby Van Dam
Debby Van Dam
GMGuido De Meyer
Guido De Meyer
Nitric oxide (NO) is a small gaseous signaling molecule responsible for maintaining homeostasis in a myriad of tissues and molecular pathways in neurology and the cardiovasculature. In recent years, there has been increasing interest in the potential interaction between arterial stiffness (AS), an independent cardiovascular risk factor, and neurodegenerative syndromes given increasingly epidemiological study reports. For this reason, we previously investigated the mechanistic convergence between AS and neurodegeneration via the progressive non-selective inhibition of all nitric oxide synthase (NOS) isoforms with N(G)-nitro-L-arginine methyl ester (L-NAME) in C57BL/6 mice. Our previous results showed progressively increased AS in vivo and impaired visuospatial learning and memory in L-NAME-treated C57BL/6 mice. In the current study, we sought to further investigate the progressive molecular signatures in hippocampal tissue via LC–MS/MS proteomic analysis. Our data implicate mitochondrial dysfunction due to progressive L-NAME treatment. Two weeks of L-NAME treatment implicates altered G-protein-coupled-receptor signaling in the nerve synapse and associated presence of seizures and altered emotional behavior. Furthermore, molecular signatures implicate the cerebral presence of seizure-related hyperexcitability after short-term (8 weeks) treatment followed by ribosomal dysfunction and tauopathy after long-term (16 weeks) treatment.